Micronbrane Medical raised $4.5 Million in Series A investment led by CDIB Capital International which operates in multiple markets in Asia and North America and has $1.2 BN+ in total assets under management

TAOYUAN CITY, TAIWAN, September 29, 2022 — Micronbrane Medical, a biotechnology start-up developing metagenomic-based technologies, today announced it raised $4.5 million in A round funding  led by CDIB Capital International which operates on multiple markets in Asia and North America and has $1.2 BN+ in total asset under management.

Micronbrane Medical, established in Feb 2020, is the first company in Taiwan focusing on clinical pathogen diagnostic tests using NGS and its own host depletion technologies with global patents.

Company launched two commercial products which include the Devin™ filter for fast and efficient depletion of host DNA interference and Kit for microbial DNA extraction. With these products the company expects to reduce the cost of sequencing up to 75% which will make infectious disease diagnosis by sequencing much more affordable for hospitals and patients.

“The Covid-19 pandemic and the recent Monkey Pox epidemic highlight the need for rapid and comprehensive identification of known and novel pathogens,” said Mencgchu Wu, Ph.D., CEO and Co-founder of Micronebrane Medical. “PaRTI-Seq™ is an all-in-one test which can identify bacteria, viruses, fungi and parasites in liquid biopsies within 24 hours. Our goal is to ensure PaRTI-Seq  can be used reliably in a diagnostic setting.”

Micronbrane Medical is now working with several global  medical centers  to validate the Pathogen Real-Time Identification by Sequencing  (PaRTI-Seq) assay, which includes full range of mNGS-grade consumables and reagents required for end-user clinical diagnostic test. The company plans to use the funding for additional product development and clinical studies around the world.

 

About Micronbrane Medical

At Micronbrane Medical, our mission is to develop genomic innovations that enrich our understanding of microorganisms to benefit human health and ensure sustainability. The company’s proprietary technologies include host specialized collection devices, novel host depletion, optimized reagents and consumables, advanced metagenomic sequencing assays, plus rapid bioinformatic analysis software. The combined Micronbrane Medical solution enables fast and accurate identification and monitoring of a broad range of microorganisms, including bacteria, fungi, viruses, and parasites. Headquartered in Taiwan, the company has partnerships and collaborations with leading academic institutions, health systems, and clinical laboratories worldwide, underscoring its commitment to transforming our relationship with the microbial world. For more information visit https://micronbrane.com/.